William Cook

Summary

Affiliation: AstraZeneca R and D

Publications

  1. doi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials
    William Cook
    Medical Affairs, AstraZeneca, Wilmington, DE 19850, USA
    Postgrad Med 125:145-54. 2013

Collaborators

Detail Information

Publications1

  1. doi request reprint Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials
    William Cook
    Medical Affairs, AstraZeneca, Wilmington, DE 19850, USA
    Postgrad Med 125:145-54. 2013
    ..This post hoc analysis sought to assess the efficacy, safety, and tolerability of saxagliptin in patients with type 2 diabetes mellitus and cardiovascular (CV) risk factors or disease (CVD)...